Promoter group allotted shares on conversion of warrants; holding at 41.45% after the allotments
Promoter & promoter group of Aarey Drugs & Pharmaceuticals disclosed allotment of shares on conversion of warrants.
- Shares acquired (first disclosure)
- 2370000 shares = 7.71% of the total voting capital
- Holding after first allotment
- 13062443 shares (42.52%), up from 10692442 shares (37.71%)
- Shares acquired (second disclosure)
- 150000 shares = 0.47%
- Holding after second allotment
- 13212443 shares (41.45%)
- Equity share capital
- 28354303 equity shares before the allotments, 31874303 equity shares after
Promoter group gets shares on warrant conversion
The promoter and promoter group of Aarey Drugs & Pharmaceuticals Ltd have disclosed an allotment of equity shares made pursuant to conversion of warrants, shared under Regulation 29(2) read with Regulation 29(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Mode of acquisition stated: ALLOTMENT PURSUANT TO CONVERSION OF WARRANTS. Allotment date stated: 30-09-2026.
What the numbers show
- First disclosure: 2370000 shares acquired, equal to 7.71% of the total voting capital. The group's holding goes from 10692442 shares (37.71%) to 13062443 shares (42.52%).
- Second disclosure: 150000 shares acquired, equal to 0.47%. The holding goes from 13062443 shares (42.52%) to 13212443 shares (41.45%).
- Equity share capital of the company is stated at 28354303 equity shares before the allotments and 31874303 equity shares after.
Why a warrant conversion matters
A warrant is a right to receive a share at a later point. When warrants are converted, the company issues fresh shares. That is different from a promoter buying shares from another investor in the market, where the total number of shares stays the same. Here the share count itself goes up, so each shareholder's percentage holding is worked out on a larger base.
How to read the holding movement
- In number of shares, the promoter group's holding rose across the two disclosures.
- In percentage terms it moved from 37.71% to 42.52% and then to 41.45%, as the allotments and the larger share capital were recorded.
Other points in the disclosure
- It is signed for and on behalf of all the promoters and the promoter group.
- All the named holders are shown in the Promoter & Promoter Group category.
- Because fresh shares have been issued, an existing shareholder's stake is spread over a larger number of shares.
Also from Aarey Drugs & Pharmaceuticals
Revised outcome: Board approves allotment of 11,50,000 equity shares on warrant conversion
7 Oct 2026
Aarey Drugs & Pharmaceuticals Ltd promoter buys 7.71% stake
5 Oct 2026
Aarey Drugs & Pharmaceuticals Ltd shareholder buys 0.47% stake, holding rises to 5.18%
5 Oct 2026
More numbers
- Shares acquired on conversion of warrants (first disclosure)2370000
- Acquired shares as % of total voting capital (first disclosure)7.71%
- Promoter group holding before first allotment10692442
- Promoter group holding % before first allotment37.71%
- Promoter group holding after first allotment13062443
- Promoter group holding % after first allotment42.52%
- Shares acquired on conversion of warrants (second disclosure)150000
- Acquired shares as % of total voting capital (second disclosure)0.47%
- Promoter group holding after second allotment13212443
- Promoter group holding % after second allotment41.45%
- Equity share capital of the company before the allotments28354303
- Equity share capital of the company after the allotments31874303
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.